ArticleMolecular biology reports2026
Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectiveNephrolithiasis is a prevalent urological disorder characterized by significant incidence and frequent recurrence. Allicin has diverse pharmacological effects; however, its precise function and underlying mechanisms in reducing kidney stone formation have not been thoroughly investigated. The present research endeavors to comprehensively examine the impact of allicin on the development of renal calculi and elucidate its underlying mechanisms.
methodsA multifaceted methodology was implemented, incorporating network pharmacology for target and pathway identification, molecular docking to evaluate binding affinities, in vitro experiments utilizing calcium oxalate-damaged HK-2 cells for assessing cellular responses, and in vivo investigations employing ethylene glycol-induced nephrolithiasis rat model to examine physiological impacts.
resultsIntegrated network pharmacological screening identified 46 overlapping targets shared by allicin and nephrolithiasis. Among these hub molecules, TNF was recognized as the central effector target, and the TNF/NF‑κB signaling axis was determined as the dominant pathway mediating the protective effects of allicin against renal crystal formation. Molecular docking confirmed that allicin moderately binds to TNF (binding energy of -2.05 kcal/mol). In vitro, allicin (200 µmol/L) improved the viability of injured HK-2 cells and decreased the levels of inflammatory factors. In vivo, allicin reduced kidney damage and calcium oxalate deposition in rats.
conclusionAllicin alleviates kidney stones by inhibiting the TNF/NF-κB pathway, providing preclinical evidence for its potential in kidney stone management. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.